Medicine and Dentistry
Cyclophosphamide
100%
Progression Free Survival
65%
Overall Survival
64%
Graft Versus Host Reaction
54%
Rituximab
51%
Transplantation
43%
Idelalisib
40%
B-Cell Chronic Lymphocytic Leukemia
40%
Disease
37%
Hodgkin's Lymphoma
34%
Lenalidomide
34%
Diffuse Large B-Cell Lymphoma
33%
Malignant Neoplasm
33%
Drug Megadose
32%
Prophylaxis
32%
Hazard Ratio
32%
Non-Hodgkin Lymphoma
29%
Arm
27%
Oncology
26%
Allotransplantation
24%
Lymphocytic Lymphoma
24%
Follicular Lymphoma
23%
Classical Hodgkin Lymphoma
23%
Human Immunodeficiency Virus
23%
Clinical Trial
21%
Nonmyeloablative Conditioning
19%
B Cell
18%
Doxorubicin
18%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
18%
Vincristine
18%
Chemotherapy-Induced Peripheral Neuropathy
17%
Mantle Cell Lymphoma
17%
Haploidentical Transplantation
17%
B-Cell Lymphoma
17%
Immunosuppressive Treatment
17%
Immunoglobulin
17%
Stem Cell Transplant
16%
Infusion
16%
Cumulative Incidence
16%
Positron Emission Tomography
15%
Methotrexate
15%
Prednisone
15%
Adverse Event
14%
Hematologic Malignancy
14%
Whole Body Radiation
14%
Brentuximab Vedotin
13%
Bone Marrow Transplantation
13%
Recurrence Free Survival
13%
Neuropathy
13%
Cancer
13%
Keyphrases
Post-transplantation Cyclophosphamide (PTCy)
84%
Relapsed or Refractory
58%
Overall Survival
47%
Confidence Interval
46%
Graft-versus-host Disease (GvHD)
45%
Chronic Lymphocytic Leukemia
43%
Allogeneic Blood or Marrow Transplantation
42%
Rituximab
36%
Progression-free Survival
30%
Allogeneic Transplantation
28%
Lenalidomide
28%
Idelalisib
28%
Nonmyeloablative
28%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
27%
Lymphoma
27%
Graft-versus-host Disease Prophylaxis
25%
Lymphoma Patients
23%
Relapsed Lymphoma
22%
Phase II Study
20%
Follicular Lymphoma
19%
Relapse-free Survival
18%
Classic Hodgkin Lymphoma
17%
Chemotherapy-induced Peripheral Neuropathy
17%
Peripheral Blood
17%
Hazard Ratio
17%
Non-relapse Mortality
16%
Mantle Cell Lymphoma
15%
Indolent non-Hodgkin Lymphoma
15%
Overall Response Rate
15%
Diffuse Large B-cell Lymphoma (DLBCL)
15%
Haploidentical Transplantation
15%
Chemotherapy
15%
Adverse Events
15%
Brentuximab Vedotin
14%
Immunosuppressive Therapy
14%
High-dose Methotrexate (HD-MTX)
13%
High Dose
13%
Transplantation
13%
Cumulative Incidence
13%
Indolent Lymphoma
13%
Retrospective Analysis
13%
Blood or Marrow Transplantation
12%
Neuropathy
12%
Maintenance Therapy
12%
Cyclophosphamide
12%
Myeloablative Conditioning
12%
Acute Lymphoblastic Leukemia
11%
Severe Aplastic Anemia
11%
Neurotoxic Chemotherapy
11%
Immunoglobulin
11%
Pharmacology, Toxicology and Pharmaceutical Science
Cyclophosphamide
85%
Overall Survival
52%
Rituximab
50%
Progression Free Survival
48%
Disease
47%
Chemotherapy
42%
Diffuse Large B Cell Lymphoma
41%
Idelalisib
40%
Nonhodgkin Lymphoma
38%
Graft Versus Host Reaction
38%
Chronic Lymphatic Leukemia
37%
Lenalidomide
28%
Malignant Neoplasm
27%
Methotrexate
25%
Doxorubicin
23%
Classical Hodgkin Lymphoma
23%
Vincristine
22%
Adverse Event
22%
Follicular Lymphoma
22%
Clinical Trial
19%
Chemotherapy-Induced Peripheral Neuropathy
19%
Neuropathy
18%
Hematologic Malignancy
17%
Phosphatidylinositol 3 Kinase
17%
Ofatumumab
17%
Symptom
16%
Paclitaxel
15%
Prednisone
14%
Oxaliplatin
14%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
12%
Tolerability
12%
Lymphocytic Lymphoma
12%
Oxaliplatin-Induced Neuropathy
12%
Etoposide
12%
Neoplasm
11%
HIV
11%
Hodgkin Disease
11%
Inotuzumab Ozogamicin
11%
Aplastic Anemia
11%
Graft Failure
10%
Neutropenia
10%
Remission
9%
Mantle Cell Lymphoma
9%
Immunosuppressive Agent
8%
B Cell Lymphoma
8%
Acute Graft Versus Host Disease
8%
Thrombocytopenia
8%
Chimeric Antigen Receptor
8%
Recurrence Free Survival
7%
Bruton Tyrosine Kinase Inhibitor
7%
